Mumbai, November 05, 2017: Dr Reddy’s Laboratories said it has launched generic Azacitidine for injection, a cancer treatment drug, in the Canadian market.
The company’s product, which is a generic equivalent of Vidaza, has been approved by Health Canada, Dr Reddy’s Laboratories said in a statement.
”Bringing azacitidine for injection to the Canadian market at this time is very important for us, as well as for our customers and their patients,” said Alok Sonig, Executive Vice-President and Head of the North America Generics business at Dr Reddy’s. ”This launch represents Dr Reddy’s commitment to make affordable injectable drugs available in Canada.” Dr Reddy’s is first to market with this azacitidine for injection in Canada.
Import milestone
United News Of India
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…